Table 1.
Diagnostic criteria, duration of disease, and previous and concomitant medications
| Patient | ACR criteria for SLE diagnosisa | Duration of SLE (years) | Previous SLE treatments | Current medications | Dose | Schedule | Start - end date |
|---|---|---|---|---|---|---|---|
| 1 | • +ANA • +dsDNA • Non-erosive arthritis • Mucosal ulcers • Malar rash • Photosensitivity • Pleurisy | 16 | • Arava • Prednisone • Methotrexate • Plaquenil • Cellcept • Depo Medrol IM injections • Benlysta SQ 3 times per week >15 months via open-label research protocol | Mobic | 15 mg | 1 tablet QD | 02/28/12 - ongoing |
| Ibuprofen | 800 mg | 1 tablet TID, PRN | 11/22/11 - ongoing | ||||
| Prednisone | 3 mg | 1 tablet QD | 09/10/12 - 11/08/12 | ||||
| Benlysta | 640 mg | IV q4 weeks | 12/21/11 - 04/18/13 | ||||
| Diclofenac Cream | 5% | Apply BID, PRN | 02/28/12 - ongoing | ||||
| Ultram | 50 mg | 1 tablet TID, PRN | 03/30/11 - ongoing | ||||
| 2 | • +ANA • Malar rash • Discoid rash • Mucosal ulcers • Non-erosive arthritis • Photosensitivity | 15 | • Thalomid • Benlysta • Methotrexate • Imuran • Quinacrine • Plaquenil • Prednisone • Cellcept | Prednisone | 3 mg | 1 tablet QD | 04/27/10 - ongoing |
| Ultram | 50 mg | 1 tablet BID, PRN | 10/02/09 - ongoing | ||||
| Benlysta | 600 mg | IV q4 weeks | 09/22/11 - 11/29/12 | ||||
| 3 | • +ANA • Pleurisy • Non-erosive arthritis • Mucosal ulcers • Discoid rash | 7 | • Depo Medrol IM injections • Plaquenil | Prednisone | 10 mg | 1 tablet QD | 09/04/12 - ongoing |
| Benlysta | 1440 mg | IV q4 weeks | 08/06/12 - ongoing | ||||
| Azulfidine | 500 mg | 3 tablets BID | 06/02/09 - ongoing | ||||
| 4 | • +ANA • Malar rash • Mucosal ulcers • Non-erosive arthritis | 1 | • Depo Medrol IM injections • Prednisone | Mobic | 15 mg | 1 tablet QD | 07/26/12 - ongoing |
| Benlysta | 760 mg | IV q4 weeks | 06/28/12 - ongoing | ||||
| Methotrexate | 20 mg | 1 tablet once weekly | 01/25/12 - ongoing | ||||
| Ultram | 50 mg | 1 tablet TID, PRN | 10/05/11 - ongoing | ||||
| Plaquenil | 200 mg | 2 tablets QD | 10/05/11 - ongoing | ||||
| Folic Acid | 1 mg | 1 tablet QD | 10/05/11 - ongoing | ||||
| 5 | • +ANA • Non-erosive arthritis • Malar rash • Mucosal ulcers | 1.5 | • Prednisone • Depo Medrol IM injections | Mobic | 15 mg | 1 tablet QD | 01/06/11 - ongoing |
| Benlysta | 1040 mg | IV q4 weeks | 11/09/11 - 01/08/13 | ||||
| Plaquenil | 200 mg | 2 tablets po QD | 04/11/11 - ongoing | ||||
| 6 | • +ANA • Non-erosive arthritis • Photosensitivity • Malar rash • Pleurisy • Mucosal ulcers | 2 | • Prednisone • Depo Medrol IM injections | Mobic | 7.5 mg | 1 tablet QD | 12/23/10 - ongoing |
| Benlysta | 1160 mg | IV q4 weeks | 02/01/12 - ongoing | ||||
| Methotrexate | 20 mg | 1 tablet once weekly | 06/08/11 - ongoing | ||||
| Folic Acid | 400 mcg | 1 tablet BID | 06/08/11 - ongoing | ||||
| 7 | • +ANA • Non-erosive arthritis • Malar rash • Mucosal ulcers • Photosensitivity | 7 | • Methotrexate • Benlysta SQ injection 1 time weekly >15 months in open- label research protocol • Plaquenil • Depo Medrol IM injections | Prednisone | 5 mg | 1 tablet QD | 10/24/12 - 12/15/12 |
| Benlysta | 840 mg | IV q4 weeks | 12/22/11 - ongoing | ||||
| Celebrex | 200 mg | 1 tablet BID | 11/26/12 - ongoing | ||||
| 9 | • +ANA • +Smith antibody • Non-erosive arthritis • Mucosal ulcers • Malar rash • Photosensitivity | 10 | • Prednisone • Depo Medrol IM injections | Benlysta | 620 mg | IV q4 weeks | 03/29/12 - ongoing |
| Plaquenil | 200 mg | 2 tablets QD | 10/13/06 - ongoing | ||||
| Methotrexate | 12.5 mg | 1 tablet weekly | 09/29/08 - ongoing | ||||
| Folic Acid | 1 mg | 1 tablet QD | 09/29/08 - ongoing | ||||
| Diclofenac Sodium | 75 mg | 1 tablet BID | 11/16/09 - ongoing | ||||
| Hydrocortisone | 10 mg | 1 tablet am | 01/2011 - ongoing | ||||
| Hydrocortisone | 5 mg | 1 tablet pm | 01/2011 - ongoing | ||||
| 10 | • +ANA • Non-erosive arthritis • Mucosal ulcers • Malar rash • Discoid rash • Neurological disorder | 8 | • Methotrexate • Quinacrine • Thalomid • Cellcept | Benlysta | 960 mg | IV q4 weeks | 11/15/11 - ongoing |
| Plaquenil | 200 mg | 2 tablets QD | 11/10/09 - ongoing | ||||
| Diclofenac Cream | 5% | apply BID | 12/20/11 - ongoing | ||||
| 12 | • +ANA • Malar rash • Photosensitivity • Non-erosive arthritis • Mucosal ulcers | 3 | • Methotrexate | Plaquenil | 200 mg | 1 tablet QD | 08/31/10 - ongoing |
| Mobic | 15 mg | 1 tablet QD | 08/31/10 - ongoing | ||||
| Doxycycline | 100 mg | 1 tablet BID | 01/25/11 - ongoing | ||||
| Prednisone | 5 mg | 1 tablet QD | 01/25/11 - ongoing | ||||
| Ultram | 50 mg | 1 tablet po PRN | 06/30/11 - ongoing |
a
Patients had to meet ≥4 of the 11 ACR criteria to meet the standards of diagnosis. The 11 criteria include: discoid rash, hematologic disorder, immunologic disorder, malar rash, neurologic disorder, non-erosive arthritis, oral ulcers, photosensitivity, pleuritis or pericarditis, positive antinuclear antibody, and renal disorder.31
BID, twice daily; IM, intramuscular; IV, intravenous; PRN, as needed; QD, once daily; SQ, subcutaneous; TID, three times daily.